Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Increases By 26.3%

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 913,100 shares, an increase of 26.3% from the January 31st total of 723,200 shares. Based on an average daily trading volume, of 2,500,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.9% of the shares of the company are sold short.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC bought a new position in Syros Pharmaceuticals during the 4th quarter valued at about $25,000. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Finally, Exome Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares in the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com started coverage on shares of Syros Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating on the stock. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Up 1.3 %

Shares of SYRS opened at $0.09 on Thursday. The company has a 50-day moving average price of $0.19 and a two-hundred day moving average price of $0.98. The stock has a market cap of $2.31 million, a price-to-earnings ratio of -0.03 and a beta of 1.29. Syros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $7.27.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.